FCP
AZN icon

Fidelis Capital Partners’s AstraZeneca AZN Stock Holding History

Fidelis Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Sell
2,142
-126
-6% -$23.7K 0.02% 376
2026
Q1 		$447K Sell
2,268
-231
-9% -$44.5K 0.03% 340
2025
Q4 		$459K Buy
2,499
+533
+27% +$93.5K 0.03% 327
2025
Q3 		$302K Buy
1,966
+139
+8% +$21K 0.02% 389
2025
Q2 		$269K Sell
1,827
-4
-0.2% -$561 0.02% 370
2025
Q1 		$255K Buy
1,831
+373
+26% +$54K 0.03% 352
2024
Q4 		$204K Sell
1,458
-7,288
-83% -$1.02M 0.02% 420
2024
Q3 		$1.35M Buy
8,746
+739
+9% +$119K 0.16% 118
2024
Q2 		$1.29M Buy
8,007
+2,466
+45% +$371K 0.18% 96
2024
Q1 		$751K Buy
5,541
+2,873
+108% +$380K 0.11% 165
2023
Q4 		$359K Buy
2,668
+469
+21% +$61K 0.08% 216
2023
Q3 		$298K Buy
2,199
+484
+28% +$66.1K 0.1% 197
2023
Q2 		$245K Buy
1,715
+367
+27% +$54K 0.09% 234
2023
Q1 		$203K Buy
+1,348
New +$181K 0.09% 236

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelis Capital Partners's AZN Position: Q2 2026 in Review

Fidelis Capital Partners reduced its AstraZeneca (AZN) stake by 5.6% in Q2 2026, selling an estimated $23.7K and leaving 2,142 shares worth $406K. The position accounts for 0.02% of the portfolio, ranked #376.

Fidelis Capital Partners first reported a position in AZN in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.35M in Q3 2024. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Fidelis Capital Partners held 2,142 shares of AstraZeneca worth $406K as of Q2 2026.
  • Fidelis Capital Partners sold 126 AstraZeneca shares in Q2 2026, an estimated $23.7K.
  • AstraZeneca made up 0.02% of Fidelis Capital Partners's portfolio in Q2 2026, its #376 holding.
  • Fidelis Capital Partners first reported a position in AstraZeneca in Q1 2023 and has held it in 14 quarters since.
  • Fidelis Capital Partners's AstraZeneca position peaked at $1.35M in Q3 2024.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.